What is the recommended Lanreotide (Somatuline Depot) dosage?

Lanreotide (Somatuline Depot) dosing varies by experience level. Beginners typically start at 60mg monthly, moderate users at 90mg monthly, and aggressive protocols use 120mg monthly.

How do you reconstitute Lanreotide (Somatuline Depot)?

Lanreotide (Somatuline Depot) comes as a pre-filled device — no reconstitution needed.

What is the half-life of Lanreotide (Somatuline Depot)?

The half-life of Lanreotide (Somatuline Depot) is ~23-30 days (depot formulation). This determines how frequently you need to dose for consistent blood levels.

Lanreotide (Somatuline Depot)

MetabolicInjectionFDA ApprovedGrade A~23-30 days (depot formulation) half-life

Somatostatin AnalogAcromegalyNeuroendocrine TumorsGEP-NETLong-Acting

Benefits

Normalizes GH and IGF-1 levels in 50-70% of acromegaly patients

Significantly prolongs progression-free survival in GEP-NETs (CLARINET trial: 53% risk reduction)

Reduces pituitary tumor volume by ≥20% in ~63% of patients (PRIMARYS trial)

Once-monthly dosing with pre-filled syringe — no reconstitution required

Controls carcinoid syndrome symptoms (diarrhea, flushing)

Well-established long-term safety profile over decades of clinical use

Half-Life

~23-30 days

Route

Injection

Frequency

Monthly

Vial Sizes

60mg, 90mg, 120mg

BAC Water

Pre-filled

Safety Grade

Grade A

Open Lanreotide (Somatuline Depot) Dosage Calculator

Calculate exact syringe units for your vial and dose

About Lanreotide (Somatuline Depot)

Lanreotide is a synthetic octapeptide analog of somatostatin, marketed as Somatuline Depot. It binds primarily to somatostatin receptor subtypes 2 (SST2) and 5 (SST5), inhibiting growth hormone (GH) secretion, reducing IGF-1 levels, and exerting antiproliferative effects on neuroendocrine cells. FDA-approved since 2007 for acromegaly and since 2014 for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The depot formulation uses a supersaturated solution that forms a gel deposit at the injection site, providing sustained drug release over 28 days.

Who Should Consider Lanreotide (Somatuline Depot)

Adults with acromegaly who have inadequate response to surgery or are not surgical candidates
Adults with unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs
Patients with carcinoid syndrome needing symptom control
Acromegaly patients as primary medical therapy when surgery is contraindicated

How Lanreotide (Somatuline Depot) Works

Lanreotide is a cyclic octapeptide that mimics natural somatostatin but with a much longer duration of action. It binds with high affinity to somatostatin receptor subtype 2 (SST2) and moderate affinity to subtype 5 (SST5), with minimal activity at SST1, SST3, and SST4. SST2 activation inhibits adenylyl cyclase, reducing intracellular cAMP and suppressing GH secretion from pituitary somatotrophs. SST2 also activates tyrosine phosphatase pathways linked to antiproliferative effects. SST5 activation reduces intracellular calcium, contributing to inhibition of hormone secretion and cell proliferation. In neuroendocrine tumors, these combined actions suppress tumor-derived hormone release and slow tumor growth.

What to Expect

Month 1

First injection

GH levels begin to decline within hours. GI side effects (diarrhea, abdominal pain) are most common during the first few injections. Serum lanreotide concentrations reach therapeutic levels within the first day.

Months 2-3

Steady-state drug levels approach with repeated dosing. GH and IGF-1 levels show measurable reduction. GI side effects often improve as the body adapts. Dose titration may be initiated based on GH/IGF-1 response.

Months 3-6

Steady-state pharmacokinetics fully established by the 4th-5th injection. Significant IGF-1 normalization expected in responders. Tumor volume reduction detectable on imaging in acromegaly patients. GEP-NET tumor stabilization assessable.

Months 6-12

Optimal hormonal control achieved with dose adjustments. PRIMARYS trial showed 63% of patients had ≥20% tumor shrinkage by 48 weeks. Long-term gallbladder monitoring should begin. Symptom improvement in acromegaly (headache, sweating, joint pain).

Year 1+

Continued long-term treatment with periodic monitoring of GH, IGF-1, liver function, glucose, thyroid function, and gallbladder ultrasound. CLARINET trial showed 65% progression-free survival at 24 months for GEP-NETs. Dose extended to every 6-8 weeks in some well-controlled acromegaly patients.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	60mg	Monthly
Moderate	90mg	Monthly
Aggressive	120mg	Monthly

Note: Lanreotide is administered as a deep subcutaneous injection every 28 days, not weekly. The "Weekly" frequency is used as the closest valid option — actual dosing is once every 4 weeks (q28d). Available as a pre-filled syringe (Somatuline Depot) in 60mg, 90mg, and 120mg strengths. Dose selection depends on GH/IGF-1 levels for acromegaly or tumor grade for GEP-NETs. Do not mix or dilute — inject the full syringe at room temperature into the upper outer quadrant of the buttock.

How to Inject Lanreotide (Somatuline Depot)

Inject deep subcutaneously into the upper outer quadrant of the buttock every 28 days. Allow syringe to reach room temperature for 30 minutes before injection. Insert the needle rapidly at a 90° angle to the full depth. Inject slowly and steadily. Alternate between left and right buttock each month. Self-injection is possible but many patients prefer healthcare provider administration. Do not inject into areas with skin disease, inflammation, or infection. The injection site should not be rubbed afterward.

Cycling Protocol

On Period

52 weeks

Off Period

0 weeks

Lanreotide is used continuously as long as clinical benefit is maintained. For acromegaly, it is typically a lifelong treatment unless surgery or radiation achieves remission. For GEP-NETs, treatment continues until disease progression or unacceptable toxicity. Dose adjustments are made based on GH/IGF-1 levels (acromegaly) or tumor response (GEP-NETs).

Pharmacokinetics

Half-Life

624h

Bioavailability

SC (deep): 69-78% (dose-dependent; 73.4% at 60mg, 69.0% at 90mg, 78.4% at 120mg)

Tmax

~24 hours (Cmax within first day); sustained therapeutic levels >1 ng/mL throughout 28-day dosing interval

Data Confidence

high

Source: FDA Prescribing Information (Somatuline Depot), Section 12.3 — terminal half-life 23 to 30 days for depot formulation

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Very common: diarrhea (35-65%), abdominal pain (34%), cholelithiasis/gallstones (14-27%), injection site reactions (15%). Common: nausea, vomiting (19%), hyperglycemia (14%), headache (16%), musculoskeletal pain (19%), hypertension (14%). Less common: flatulence, dizziness (9%), depression (7%), bradycardia, hypothyroidism. GI side effects are dose-dependent and often the most bothersome. Gallstones develop because somatostatin analogs reduce gallbladder contractility — ultrasound monitoring is recommended.

Contraindications

Known hypersensitivity to lanreotide or any component of the formulation
Pregnancy (FDA Category C — may cause fetal harm based on animal data)
Breastfeeding — not recommended; unknown if lanreotide is excreted in human milk
Uncontrolled diabetes mellitus (may worsen glycemic control)
Severe hepatic impairment (dose adjustment required in moderate impairment)
Severe renal impairment (dose adjustment required)

Drug Interactions

Insulin and oral hypoglycemics — lanreotide may alter glucose regulation; dose adjustments of antidiabetic drugs may be needed
Cyclosporine — decreased blood levels of cyclosporine; monitor levels closely
Bromocriptine — increased bioavailability of bromocriptine; monitor for dopamine agonist side effects
Beta-blockers, calcium channel blockers, and other drugs that slow heart rate — additive bradycardia risk
Drugs metabolized by CYP3A4 — somatostatin analogs may reduce metabolic clearance of some substrates
Warfarin and other anticoagulants — monitor closely as absorption may be affected